3-Nitrotriazole-based piperazides as potent antitrypanosomal agents

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• Chagas disease and human African trypanosomiasis are significant global health concerns.
• Existing treatments for trypanosomal diseases have limitations, including toxicity and resistance.
• Novel therapeutic strategies are urgently needed to combat these parasitic infections.

Purpose of the Study:

• To synthesize and evaluate novel 3-nitro-1H-1,2,4-triazole-based piperazides as antitrypanosomal agents.
• To assess the antiparasitic activity and selectivity of these compounds against Trypanosoma cruzi, Trypanosoma brucei rhodesiense, and Leishmania donovani.
• To investigate the potential of these compounds as prodrugs activated by trypanosomal nitroreductases.

Main Methods:

• Synthesis of linear 3-nitro-1H-1,2,4-triazole-based piperazides and bisarylpiperazine-ethanones.
• In vitro screening of synthesized compounds for activity against Trypanosoma cruzi, T. brucei rhodesiense, and Leishmania donovani.
• Evaluation of compound toxicity against host L6 cells and assessment of ADMET characteristics.
• In vivo testing of a selected potent compound in an acute murine model of Chagas disease.

Main Results:

• Most 3-nitrotriazole derivatives exhibited potent and selective activity against Trypanosoma cruzi.
• Two compounds showed moderate and selective activity against Leishmania donovani.
• Seven of 13 compounds were significantly more potent antichagasic agents than benznidazole, with improved host cell safety profiles.
• A potent compound demonstrated in vivo antichagasic activity in a murine model, though statistical significance was limited by high parasite burden variability.

Conclusions:

• 3-Nitrotriazole-based piperazides represent a novel class of potentially effective antitrypanosomal agents.
• These compounds function as prodrugs, efficiently utilized by trypanosomal type I nitroreductases.
• The synthesized piperazides offer a promising, potentially more affordable alternative to existing treatments for Chagas disease and other trypanosomal infections.